177210-33-2

Basic information

• Product Name: 5-HYDROXY-2H-1,4-BENZOXAZIN-3(4H)-ONE
• Synonyms: 5-HYDROXY-2H-1,4-BENZOXAZIN-3(4H)-ONE;5-Hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one
• CAS NO: 177210-33-2
• Molecular Formula: C₈H₇NO₃
• Molecular Weight: 165.15
• Mol File: 177210-33-2.mol

Chemical Properties

• Boiling Point: 390.8 °C at 760 mmHg
• Flash Point: 190.1 °C
• Appearance: /
• Density: 1.396 g/cm³
• Vapor Pressure: 1.15E-06mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-HYDROXY-2H-1,4-BENZOXAZIN-3(4H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-HYDROXY-2H-1,4-BENZOXAZIN-3(4H)-ONE(177210-33-2)
• EPA Substance Registry System: 5-HYDROXY-2H-1,4-BENZOXAZIN-3(4H)-ONE(177210-33-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 177210-33-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
5-Hydroxy-2H-1,4-benzoxazin-3(4H)-one is used as a potential pharmaceutical agent for its bioactive properties. Its antibiotic activity and antifungal properties make it a candidate for the development of new drugs, particularly in the context of plant defense mechanisms.
Used in Plant Defense Mechanisms:
In the agricultural industry, 5-Hydroxy-2H-1,4-benzoxazin-3(4H)-one is used as a natural defense compound for plants. Its significant antifungal properties contribute to the protection of crops, such as wheat and maize, against fungal infections, thereby enhancing crop health and yield.
Used in Chemical Research:
5-Hydroxy-2H-1,4-benzoxazin-3(4H)-one is used as a subject of chemical research for its unique chemical properties. Its stability and non-toxic nature make it an interesting compound for studying the structure and function of hydroxamic acids and their potential applications in various fields.

InChI:InChI=1/C8H7NO3/c10-5-2-1-3-6-8(5)9-7(11)4-12-6/h1-3,10H,4H2,(H,9,11)

Upstream product

• 857264-71-2 2-chloro-N-(2,6-dihydroxyphenyl)acetamide 
• 3163-15-3 2-aminoresorcinol 
• 79-04-9 chloroacetyl chloride 
• 601-89-8 2-nitroresorcinol 
• 634-60-6 2-aminoresorcinol hydrochloride 

Downstream Products

• 1338065-05-6 3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-5-yl 4-(trifluoromethyl)benzylcarbamate 
• 1179336-41-4 (R)-8-(2-azido-1-hydroxyethyl)-5-(benzyloxy)-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 1179336-51-6 (S)-8-(2-azido-1-hydroxyethyl)-5-(benzyloxy)-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 1092407-76-5 8-[(R)-2-azido-1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-5-benzyloxy-4H-benzo[1,4]oxazin-3-one 

Relevant articles and documents

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists

By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the β2-adrenoceptor agonists procaterol and BI-167107 (4), we designed and synthesized a collection of novel hydroxy-substituted heteroarylpiperazines and heteroarylhomopiperazines with high dopamine D2 receptor (D2R) affinity. In contrast to the weak agonistic behavior of aripiprazole, these ligands are capable of effectively mimicking those interactions of dopamine and the D2R that are crucial for an active state, leading to the recruitment of β-arrestin-2. Interestingly, some ligands show considerably lower intrinsic activity in guanine nucleotide exchange experiments at D2R and consequently represent biased agonists favoring β-arrestin-2 recruitment over canonical G protein activation. The ligands' agonistic properties are substantially driven by the presence of an endocyclic H-bond donor.

Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists

Aiming to discover dual-acting β2 adrenergic/dopamine D2 receptor ligands, a structure-guided approach for the evolution of GPCR agonists that address multiple targets was elaborated. Starting from GPCR crystal structures, we describ

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical com-positions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"

The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active

TRPV1 vanilloid receptor antagonists with a bicyclic portion

The invention discloses compounds of formula I wherein Y s selected from a group of formula and W, Q, n, R1, R2, R3, U1-U5 have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1. 1.

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.